Q: What is Eli Lilly 2024/Q2 Earnings Preview?
TigerGPT Answer: ### Eli Lilly (LLY) Earnings Call Summary
#### Forecast Data
- **Earnings Per Share (EPS):** $2.70 (Q2 2024)
- **Prior Year EPS:** $2.11 (Q2 2023)
- **Percentage Change:** +27.96%
- **Total Revenue:** $9,948,664,070.00 (Q2 2024)
- **Prior Year Revenue:** $8,312,100,000.00 (Q2 2023)
- **Percentage Change:** +19.68%
- **EBIT:** $2,990,738,540.00 (Q2 2024)
- **Prior Year EBIT:** $2,252,100,000.00 (Q2 2023)
- **Percentage Change:** +32.82%
**Significance:** The significant increases in EPS, total revenue, and EBIT indicate strong financial performance and growth for Eli Lilly compared to the same period last year. This suggests effective cost management and successful product sales.
#### Quarterly Important News
1. **Negative News:**
- **Alzheimer's Drug Impact:** The European Medicines Agency's rejection of a competitor's Alzheimer's drug could affect Eli Lilly's own Alzheimer's drug, Donanemab, which recently received FDA approval.
- **Stock Price Drop:** On July 30, 2024, Eli Lilly's stock dropped by 1.10% following the announcement of a $3.2 billion acquisition of Morphic, which was at a 79% premium to its closing price.
2. **Positive News:**
- **Podcast Highlight:** Zacks Market Edge Podcast discussed Eli Lilly's strong performance and stock run over the last five years, emphasizing that the stock's rise does not necessarily indicate a bubble.
**Impact Analysis:** The negative news could create short-term volatility and investor concerns, while the positive news highlights the company's strong market position and potential for continued growth.
#### Forecast Viewpoints
- **Eli Lilly (LLY) Earnings Expected to Grow:**
- **Summary:** Wall Street expects a year-over-year increase in earnings on higher revenues for Eli Lilly. The earnings report, expected on August 8, 2024, could influence the stock price based on how actual results compare to estimates.
- **Reference Link:** Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
#### Stock Trend Analysis
- **Latest Price:** $804.46 (August 5, 2024)
- **Support Price:** $880.00 (August 2, 2024)
- **Resistance Price:** $777.00 (August 2, 2024)
- **Quarterly Stock Price Fluctuation:** +16.38% (March 31, 2024 - June 29, 2024)
- **Analyst Target Price:** Mean: $927.45, Low: $600.00, High: $1117.00
**Trend Analysis:** The stock has shown significant volatility with a notable increase over the past quarter. The current price is below the support level, indicating potential downward pressure. However, the high target price suggests optimism among analysts.
#### Options Large Order Analysis
- **Options Bulk Order:**
- **Put Option:** LLY 20240726 912.5 put, Volume: 1120, Order Type: Sell
**Analysis:** The presence of a large sell order for put options suggests a bearish sentiment among options traders, indicating a possibility that the financial report might fall below expectations.
#### Analyst Ratings and Target Price Forecast
- **Analyst Ratings:** 7 recommend, 15 buy, 6 hold
- **Valuation Status:** The stock is currently seen as having a high target price, indicating that analysts believe it has room to grow. However, the mixed ratings suggest some caution.
**Valuation Analysis:** Based on the target prices and analyst ratings, Eli Lilly is considered to be at a standard valuation with potential for growth. The upcoming financial report will be crucial in determining if the stock can meet or exceed these expectations.
### Comprehensive Conclusion
Eli Lilly is expected to show strong financial performance in Q2 2024, with significant increases in EPS, revenue, and EBIT compared to the previous year. Despite some negative news and short-term stock volatility, the overall outlook remains positive, supported by analyst ratings and target prices. However, the bearish sentiment in options trading suggests caution. Investors should closely monitor the upcoming earnings report and management's discussion for further insights.
**Disclaimer:** The above content is generated by the AI robot TigerGPT and does not represent any personal views. The content is for reference only and does not constitute any investment advice.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
